Literature DB >> 31475298

Angiotensin Receptor-Neprilysin Inhibition (ARNI) Therapy and Reverse Remodeling in Heart Failure With Reduced Ejection Fraction.

Mark H Drazner1.   

Abstract

Entities:  

Year:  2019        PMID： 31475298     DOI： 10.1001/jama.2019.12662

Source DB:  PubMed          Journal:  JAMA        ISSN： 0098-7484            Impact factor:   56.272


× No keyword cloud information.
  2 in total

1.  A clinical experience of Indian patients with heart failure with reduced left ventricular ejection fraction using an angiotensin receptor-neprilysin inhibitor [ARNI] on an outpatient basis.

Authors:  Pankaj Jariwala; Arshad Punjani; Harikishan Boorugu; Dilip Babu Madhawar
Journal:  Indian Heart J       Date:  2021-01-06

2.  Cardio-renal benefits of sacubitril/valsartan in patients with advanced chronic kidney disease: experience in daily clinical practice.

Authors:  María Dolores Martínez-Esteban; Teresa Vázquez-Sánchez; Daniel Gaitán-Román; Domingo Hernández; Rafael Pozo-Álvarez; Alicia Moreno-Ortiz; Juana Alonso-Titos; Guillermo Martín-Reyes; Pedro Ruiz-Esteban
Journal:  BMC Nephrol       Date:  2022-08-23       Impact factor: 2.585
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.